Research Summary
My research falls into two overlapping areas: (i) industrial
organization and competition economics (mostly
applied to the health sector. i.e., hospitals, pharmaceuticals, etc.
but not exclusively), and (ii) health outcomes and health policies. The
latter also spill into issues of education, gender, and racial equity.
Some of my recent work in pharmaceuticals focuses on firm strategies
and how they impact consumer welfare, firm profits, and growth. I have
worked on the valuation/welfare effects of introducing generics and second-generation (`me-too') drugs
in a product market, the impact
of additional presentations on the growth of a business unit, and
now more recently on entry
deterring effects of presentation proliferation and of product hopping.
I have also worked on pay-for-delay
deals in the European and American legal contexts and the cost of such (anticompetitive)
deals. One of the _blank contributions of this work is the policy
simulations that show which legislative changes are likely to make
anti-competitive deals not possible and which might make the situation
worse.
Concurrently, I am also working on policies to address the rise of antibacterial resistance via
managing the demand for broad- vs narrow-spectrum antibiotics. I
also have current work on evaluating alcohol regulations such as a ban on non-linear pricing or
establishing price floors
to curb excessive alcohol consumption and its heterogenous impact.
Working papers/work in progress
- "Antibiotic consumption in the UK and the cost of shifting demand
away from broad-spectrum drugs" (with Franco Mariuzzo and Weijie Yan).
CCP Working Paper 19-3. R&R at International Journal of
IndustrialOrganization. (Download latest
wp-version from here.)
- "Do the poor pay disproportionately more for increasing market
concentration? A study of retail petroleum markets" (with Sean Ennis,
Franco Mariuzzo, and Peter Ormosi). March 2022. R&R at Journal of
Industrial Economics. (Download latest
wp-version from here.)
- "Proliferation and entry deterrence" (with Weijie Yan). CCP
Working Paper 20-04. (former title: "Product line extensions
under the threat of entry: evidence from the UK pharmaceuticals
market") (Download latest wp-version
from here.)
- "Discrimination in healthcare: A field experiment with Pakistan's
Transgender community" (with Husnain F. Ahmad and Sheheryar
Banuri). August 2021. R&R at Labour Economics. (Download latest wp-version from here.)
- "Merger review using online experiments'' (Stefan Penczynski and
Janithe Siriwardana). In preparation. (Download latest slides from here.)
- "Medicine procurement with dynamic reserve price mechanism''
(tentative title) (with Sean Ennis, Carlos Vega and Tim Salmon). In
preparation.
- "Grim reaper or cost shifter: dynamic medicine auctions in the
Philippines'' (tentative title) (with Sean Ennis, Carlos Vega and Tim Salmon). In
preparation.
- "Retrospective merger evaluation: GSK-Pfizer consumer health in
Philippines'' (tentative title) (with Sean Ennis, Carlos Vega and Weijie Yan). In
preparation.
- "Estimating demand for zero priced products and the value of
personal data" (with Michael Kummer). In preparation. (Download latest slides from here.)
Publications
- "Banning volume discounts to curb excessive consumption: A
cautionary tale" (with Paul Dobson, Marcello Morciano, and Marc
Suhrcke). European Economic Review 156-104480. July 2023.
(Download latest wp-version from
here.)
- "Innovation and growth in the UK pharmaceuticals: the
case of product and marketing introductions" (with Franco Mariuzzo
and Ann Rita Bennato). Small
Business Economics, 57(1) 603-634. 2021. (Download last wp-version from here.)
- "Entry
limiting agreements for pharmaceuticals: pay-to-delay and authorized
generic deals'' (with Franco Mariuzzo and Arnold Polanski). Journal of Economics and Management
Strategy, 29(3) 516-542, Fall 2020. (Download last wp-version from here.)
- "Demand estimation and merger simulations for drugs:
Logits v. AIDS" (with Franco Mariuzzo). International Journal of Industrial
Organization, 61 (November), 653-685, 2018. (Download last wp-version from here.)
- Can
drug price hikes via debranding be prevented?" (with Bruce Lyons). Prescriber,
28(4), 44-46, April, 2017. (Download last
wp-version from here.)
- "Selective
admission into stroke unit and patient outcomes: a tale of four cities"
(with I Wellwood, A Rudd, P Langhorne, M
Dennis and CWolfe). Health Economics
Review,
4(1), 1-10, 2013. (Download last wp-version
from here.)
- "What
is the price of pay-to-delay deals?" Journal of Competition Law and Economics,
9(3), 739-753, 2013. (Download last wp-version
from here.)
- "Entry
in the ADHD drugs market: Welfare impact of generics and me-toos"
(with Gary Fournier). Journal of
Industrial Economics, 61(2), 339-392, 2013. (Download last wp-version from here.)
- "School accountability laws and consumption of
psychostimulants" (with Helen Schneider). Journal of Health Economics, 30(2),
355-372, 2011. (Download last wp-version
from here.)
- "Managed care and the adoption of technology: The case
of cardiac catheterization". International
Journal of Industrial Organization, 27(2), 223-237, March, 2009.
(Download last wp-version from here.)
- "Risk factors for discontinuing drug therapy among
children with ADHD" (with Frank Heiland, Peter Levine and Tom Ray).
Health Services and Outcomes
Research Methodology, 8(3), 134-158, September, 2008. (Download last wp-version from here.)
- "Open versus closed firms and the dynamics of industry
evolution" (with Ashish Arora). Journal
of Industrial Economics, 55(3) 499-527, September, 2007.
(Download last wp-version from here.)
- "Government
health expenditures and health outcomes" (with Yunwei Gai and Pablo
Gottret). Health
Economics, 16(3),257-273, March, 2007. (Download last wp-version from here.)
- "Attention-deficit/hyperactivity
disorder in children: Excess costs before and after initial diagnosis
and treatment" (with Tom Ray, Peter Levine, Lisa Croen, Teh-wei Hu
and Laurel Habel). Archives of
Pediatrics & Adolescent Medicine, 160(10), 1063-1069, 2006.
- "An
analysis of the significant variation in psychostimulant use across the
U.S." (with Rick Mayes and Richard Scheffler). Journal of Pharmacoepidemiology and Drug
Safety, 14(4), 267-275,
2005.
Reports and Chapters
- "Assessing the impact
of health care expenditures on mortality using cross-country data"
(with Ryota Nakamura, James Lomas, Karl Claxton, Rodrigo Moreno-Serra,
and Marc Suhrcke) in Global Health Economics: Shaping Health Policy In
Low- And Middle-income Countries 2020. World Scientific Publishing Co.
Ltd, pp.3-49. (Download last wp-version
from here.)
- "Evaluating
wholesale and retail mergers in pharmaceuticals" (with Franco
Mariuzzo). OECD's Global Forum on Competition,
DAF/COMP/GF(2014)4, February, 2014. (Download last
wp-version from here.)
- "Improving
health outcomes" (with Yunwei Gai and Pablo Gottret) in Health
Financing Revisited: A Practitioner's Guide by Pablo Gottret and George
Schieber. World Bank, Washington, D.C., 2006. (Download last wp-version from here.)
Retired papers
This page
was last updated on Aug/18/2022